Silence Therapeutics has named Georg Buchner as vice president of business development.
In this role, he will work with the company's chief business officer to broaden its collaborations with pharmaceutical and biotech firms.
By Doug Macron
Silence Therapeutics this week announced that it has signed a deal under which Mirna Therapeutics will evaluate two of its proprietary delivery technologies for use with Mirna's therapeutic microRNA mimics.
Silence Therapeutics said last week that it has received a Japanese patent covering methods for screening a therapeutic agent to treat diseases, such as cancer, related to increased Pl3-kinase pathway activity.